Approvals in 2016: questioning the clinical benefit of anticancer therapies

被引：28
作者：
Booth, Christopher M. [1 ,2 ]
Del Paggio, Joseph C. [3 ]
机构：
[1] Queens Univ, Dept Oncol Sci, Univ Ave, Kingston, ON K7L 3N6, Canada
[2] Queens Univ, Dept Publ Hlth Sci, Univ Ave, Kingston, ON K7L 3N6, Canada
[3] Univ Toronto, Div Med Oncol, Dept Med, Kings Coll Circus, Toronto, ON M5S, Canada
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2017年 / 14卷 / 03期
关键词：
MEDICAL ONCOLOGY; REFLECTIONS; SOCIETY; TRIALS;
D O I：
10.1038/nrclinonc.2017.18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with cancer expect to derive a meaningful clinical benefit from anticancer treatments, especially considering that such therapies are associated with adverse events and, often, substantial financial costs. We have evaluated new anticancer agents approved by the FDA in 2015 and 2016 using the ESMO Magnitude of Clinical Benefit Scale and ASCO Value Framework, and conclude that many agents only offer marginal value.
引用
收藏
页码：135 / 136
页数：2
相关论文
共 11 条
  • [1] Reflections on medical oncology: 25 years of clinical trials - Where have we come and where are we going?
    Booth, Christopher M.
    Tannock, Ian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) : 6 - 8
  • [2] Progression-Free Survival: Meaningful or Simply Measurable?
    Booth, Christopher M.
    Eisenhauer, Elizabeth A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) : 1030 - 1033
  • [3] Evolution of the Randomized Controlled Trial in Oncology Over Three Decades
    Booth, Christopher M.
    Cescon, David W.
    Wang, Lisa
    Tannock, Ian F.
    Krzyzanowska, Monika K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) : 5458 - 5464
  • [4] A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
    Cherny, N. I.
    Sullivan, R.
    Dafni, U.
    Kerst, J. M.
    Sobrero, A.
    Zielinski, C.
    de Vries, E. G. E.
    Piccart, M. J.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (08) : 1547 - 1573
  • [5] Do contemporary randomized controlled trials meet ESMO thresholds for clinically meaningful benefit?
    Del Paggio, J. C.
    Azariah, B.
    Sullivan, R.
    Hopman, W.
    James, F. V.
    Roshni, S.
    Tannock, I.
    Booth, C.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [6] Progress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception
    Saltz, Leonard B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (31) : 5020 - 5021
  • [7] Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
    Schlumberger, Martin
    Tahara, Makoto
    Wirth, Lori J.
    Robinson, Bruce
    Brose, Marcia S.
    Elisei, Rossella
    Habra, Mouhammed Amir
    Newbold, Kate
    Shah, Manisha H.
    Hoff, Ana O.
    Gianoukakis, Andrew G.
    Kiyota, Naomi
    Taylor, Matthew H.
    Kim, Sung-Bae
    Krzyzanowska, Monika K.
    Dutcus, Corina E.
    de las Heras, Begona
    Zhu, Junming
    Sherman, Steven I.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (07) : 621 - 630
  • [8] Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
    Schnipper, Lowell E.
    Davidson, Nancy E.
    Wollins, Dana S.
    Blayney, Douglas W.
    Dicker, Adam P.
    Ganz, Patricia A.
    Hoverman, J. Russell
    Langdon, Robert
    Lyman, Gary H.
    Meropol, Neal J.
    Mulvey, Therese
    Newcomer, Lee
    Peppercorn, Jeffrey
    Polite, Blase
    Raghavan, Derek
    Rossi, Gregory
    Saltz, Leonard
    Schrag, Deborah
    Smith, Thomas J.
    Yu, Peter P.
    Hudis, Clifford A.
    Vose, Julie M.
    Schilsky, Richard L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) : 2925 - +
  • [9] Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer
    Seruga, B.
    Hertz, P. C.
    Wang, L.
    Booth, C. M.
    Cescon, D. W.
    Krzyzanowska, M.
    Tannock, I. F.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (07) : 1411 - 1418
  • [10] Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
    Tap, William D.
    Jones, Robin L.
    Van Tine, Brian A.
    Chmielowski, Bartosz
    Elias, Anthony D.
    Adkins, Douglas
    Agulnik, Mark
    Cooney, Matthew M.
    Livingston, Michael B.
    Pennock, Gregory
    Hameed, Meera R.
    Shah, Gaurav D.
    Qin, Amy
    Shahir, Ashwin
    Cronier, Damien M.
    Ilaria, Robert, Jr.
    Conti, Ilaria
    Cosaert, Jan
    Schwartz, Gary K.
    [J]. LANCET, 2016, 388 (10043) : 488 - 497
12